US Patent Issued to Eligo Bioscience on Feb. 4 for "Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins" (French Inventors)

ALEXANDRIA, Va., Feb. 5 -- United States Patent no. 12,214,070, issued on Feb. 4, was assigned to Eligo Bioscience (Paris).

"Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins" was invented by Antoine Decrulle (Paris) and Xavier Duportet (Paris).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least on...